FDA Panel To Weigh Non-Inferiority Trial Margin In Review Of J&J’s Antibiotic Doribax

FDA's Anti-Infective Drugs Advisory Committee will consider the merits of a 20 percent non-inferiority margin based on clinical response in patients with nosocomial and ventilator-associated pneumonia.